-
10x Genomics partners with Brigham & Women's for autoimmune study
-
10x Genomics partners with Dana-Farber for cancer diagnostics research
-
10X Genomics (TXG) PT Raised to $21 at BofA Securities
-
CareDx partners with 10x Genomics on transplant rejection research program
-
Morgan Stanley Assumes 10X Genomics (TXG) at Equalweight Citing Reasonable Valuation
-
10x Genomics names Randy Wu as general counsel, Eric Whitaker retires
-
10x Genomics (TXG) Tops Q3 EPS by 7c, Beats on Revenue; Offers Q4 Revenue Guidance
-
10x Genomics launches enhanced Chromium Flex assay for single cell research
-
10x Genomics partners with Anthropic to integrate analysis tools into Claude
-
Piper Sandler Starts 10X Genomics (TXG) at Neutral
-
10x Genomics launches Xenium Protein for RNA and protein analysis
-
10x Genomics (TXG) Tops Q2 EPS by 65c, provides guidance
-
Canaccord Genuity Reiterates Buy Rating on 10X Genomics (TXG)
-
Citi names 3 stocks as its new top picks in the Life Science sector
-
10x Genomics (TXG) Announces Patent Litigation Settlement Agreement with Bruker
-
10X Genomics (TXG) PT Lowered to $15 at Canaccord Genuity
-
10x Genomics (TXG) Tops Q1 EPS by 19c, provides guidance
-
10x Genomics (TXG) Secures Injunction Against Parse Biosciences' Planned ATAC Products
-
10x Genomics (TXG) 999 contracts of August 17.50 calls trade
-
10X Genomics (TXG) PT Lowered to $20 at Citi
-
10X Genomics (TXG) PT Lowered to $18 at Canaccord Genuity
-
10x Genomics (TXG) Misses Q4 EPS by 9c, provides guidance
-
10x Genomics (TXG) Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
-
U.S. District Court Awards 10x Genomics (TXG) Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products
-
Canaccord Genuity Reiterates Buy Rating on 10X Genomics (TXG)
-
10x Genomics (TXG) Tops Q3 EPS by 4c, Misses on Revenue; Offers FY24 Revenue Guidance
-
TD Cowen Reiterates Hold Rating on 10X Genomics (TXG)
-
TD Cowen Reiterates Hold Rating on 10X Genomics (TXG)
-
10X Genomics (TXG) PT Lowered to $20 at Canaccord Genuity
-
Citi Reiterates Buy Rating on 10X Genomics (TXG)
-
BofA Securities Reiterates Neutral Rating on 10X Genomics (TXG)
-
After-hours movers: 10x Genomics, AZZ, Inc., Applied Digital, and more
-
10x Genomics (TXG) sees revenue of approximately $151.7 million for the third quarter
-
TD Cowen Reiterates Hold Rating on 10X Genomics (TXG)
-
Canaccord Genuity Reiterates Buy Rating on 10X Genomics (TXG)
-
10X Genomics (TXG) PT Lowered to $46 at Morgan Stanley
-
10x Genomics (TXG) Announces Leadership Changes
-
10X Genomics (TXG) PT Lowered to $32 at Canaccord Genuity
-
Jefferies Upgrades 10X Genomics (TXG) to Buy
-
JPMorgan Downgrades 10X Genomics (TXG) to Neutral
-
10X Genomics (TXG) PT Lowered to $25 at Stifel
-
Life Science Tools & Diagnostics stocks: Q2 earnings preview
-
Deutsche Bank Downgrades 10X Genomics (TXG) to Hold
-
TD Cowen Reiterates Hold Rating on 10X Genomics (TXG)
-
10x Genomics (TXG) Declines After Illumina (ILMN) Acquires Fluent BioSciences
-
Wolfe Research Downgrades 10X Genomics (TXG) to Peerperform
-
10x Genomics (TXG) Begins Commercial Shipments of Xenium Prime 5K Pan-Tissue and Pathways Panel

